FDA Calls Roche’s Arthritis Drug Actemra Effective Ahead Of Panel Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
First-in-class interleukin-6 receptor inhibitor may sidestep safety concerns seen with anti-TNFs.